Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by sah1on Jan 11, 2017 12:07pm

249 Views

Post# 25694304

RE:short term

Short term catalysts include:
- Read out from Alstrom study (Jan)
-Read out from IPF study (Feb)
-Orphan drug designations (Pg/ IAIP)
-complete filing of BLA for Pg (Jan/Feb)

But the big catalyst in the short term is a regional partnership deal on 4050 with $$$ upfront:-)

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity